Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: J Thorac Oncol. 2021 Jul 12;16(10):1759–1764. doi: 10.1016/j.jtho.2021.06.024

Figure 1. Steroid refractory/resistant irAEs.

Figure 1.

A. The duration of the steroid refractory/ resistant irAE, systemic steroids, and additional immunosuppressant in 51 patients with lung cancer grouped by type of irAE ordered by duration of irAE. Boxes to the left show (1) baseline autoimmune condition (Bl Ai), (2) prior thoracic radiation therapy (TRT), (3) best overall response (BOR), and (4) treatment received (PD-1 blockade monotherapy [IOx1], combined checkpoint blockade [IOx2], or chemo-immunotherapy [c+IO]). ITP: immune thrombocytopenic purpura; PR: partial response; SD: stable disease; PD: progressive disease, MMF: mycophenolate mofetil, IVIG: intravenous immunoglobulin, ICB: immune checkpoint blockade. B. The proportion of patients who improved from their steroid refractory/ resistant irAE at 90 days after the start of the second immunosuppressant grouped by type of irAE and treatment. The size of the circle represents the number of patients. The size of the arc within each circle represents the % improved.